Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume

"We have now delivered our 25th quarter of impressive growth in both revenue and volume, while continuing to invest in new technologies that further our position as a leader in the rapidly evolving genetics industry," said
Second Quarter 2019 Financial Results
- Accessioned more than 111,000 samples in the second quarter of 2019, representing a 52% increase over the more than 73,000 samples in the second quarter of 2018. Billable volume was nearly 111,000 in the second quarter of 2019
- Generated revenue of
$53.5 million in the second quarter of 2019, representing a 43% increase over the second quarter of 2018 revenue of$37.3 million - Reported the average cost per sample at
$252 in the second quarter of 2019, representing a 10% reduction from a$279 average cost per sample in the second quarter of 2018 - Achieved gross profit of
$25.5 million in the second quarter of 2019 compared to$16.9 million in gross profit in the second quarter of 2018
Total operating expenses, which exclude cost of revenue, for the second quarter of 2019 were
For the second quarter of 2019,
As of
- Reduced patient-pay pricing for its non-invasive prenatal screening (NIPS) to
$99 , increasing access to testing for women in early pregnancy - Announced the addition of supplemental RNA testing for variants of uncertain significance (VUS), beginning with patients undergoing cancer testing, to contribute to research and further reduce the uncertainty inherent in genetic testing results
- Launched
Invitae's direct channel to make it easier for customers to order and receive the same high-quality, medical genetic testing fromInvitae that experts use and trust - Continued progress with payers, as
Invitae was named one of seven labs in UnitedHealthcare's (UHC) Preferred Lab Network (PLN), effective as ofJuly 1 , 2019j. The PLN was designed to make it easier for providers to choose from UHC's broader network of more than 300 labs, based on a rigorous quality review process. Services accessed through the PLN are at a lower average cost than other lab providers - Presented various studies at
The American College of Medical Genetics and Genomics (ACMG) AnnualClinical Genetics Meeting generated by researchers fromInvitae - Shared data on the limitations of a direct-to-consumer strategy testing that detects only three of the thousands of genetic variants in BRCA1 and BRCA2 associated with hereditary breast and ovarian cancer (HBOC) risk, showing this strategy results in a clinical false negative rate of approximately 90% of those at risk for HBOC
- Shared data from more than 113,000 patients that support broadening genetic testing guidelines to include patients with potentially actionable germline variants that are missed when clinicians adhere to current guidelines
- Presented research at the
American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the importance of germline multigene panel testing in guiding therapy for expanding groups of cancer patients can impact patient outcomes and inform surgical strategy, treatments, and clinical trial eligibility - Continued investment in M&A to drive technologies to scale the business and improve quality
Acquired Singular Bio, Inc. , a privately held company developing single molecule detection technology enabling lower costs and expanded use of high-quality cell-free, nucleic acid analysis, initially for application in NIPSAcquired Jungla Inc. , a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that further enhancesInvitae's genetic variant interpretation and ability to deliver high-quality, more affordable genetic testing- Extended
Invitae's genome network with the addition of 12 new biopharma partnership programs in the second quarter of 2019 - Launched ID YOUR IRD, an initiative with Spark Therapeutics, to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness caused by inherited genetic changes
- Announced the availability of its Detect programs to provide no-charge genetic testing to improve diagnosis and treatment in four conditions: muscular dystrophy, hereditary prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases
- Announced the appointment of
Sean George as the new chairman of the board of directors and the retirement of executive chairmanRandy Scott , effectiveSeptember 1, 2019
"During my 35 years in the biotech industry, it has been amazing to watch the genomics field emerge from the early days of the human genome project to now affecting millions of lives around the world," said
"Given the stage of growth we're in, we are confident in our ability to scale as we bring genetics to mainstream medicine, and Randy's leadership and vision have been central to getting us here," said
Webcast and Conference Call Details
Management will host a conference call and webcast today at
The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.
About
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's financial results for the quarter ended
Non-GAAP Financial Measures
To supplement
Non-GAAP research and development expense, non-GAAP general and administrative expense and non-GAAP net loss exclude acquisition-related stock-based compensation related to inducement grants, post-combination expense related to the acceleration of equity grants in connection with the company's business combinations, and acquisition-related income tax benefits. These non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures.
Cash burn excludes (1) changes in marketable securities other than investments made in privately held companies, (2) cash received from equity financings, including proceeds from a public offering of common stock in
In addition, other companies, including companies in the same industry, may not use cash burn, non-GAAP research and development and general and administrative expense, or non-GAAP net loss or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the table below.
|
|
|||||||
|
Consolidated Balance Sheets |
|||||||
|
2019 |
2018 |
||||||
|
Assets |
|||||||
|
Current assets: |
|||||||
|
Cash and cash equivalents |
$ |
247,000 |
$ |
112,158 |
|||
|
Marketable securities |
800 |
13,727 |
|||||
|
Accounts receivable |
23,143 |
26,296 |
|||||
|
Prepaid expenses and other current assets |
16,976 |
13,258 |
|||||
|
Total current assets |
287,919 |
165,439 |
|||||
|
Property and equipment, net |
29,021 |
27,886 |
|||||
|
Operating lease assets |
40,228 |
— |
|||||
|
Restricted cash |
6,243 |
6,006 |
|||||
|
Intangible assets, net |
57,832 |
30,469 |
|||||
|
|
76,556 |
50,095 |
|||||
|
Other assets |
5,103 |
3,064 |
|||||
|
Total assets |
$ |
502,902 |
$ |
282,959 |
|||
|
Liabilities and stockholders' equity |
|||||||
|
Current liabilities: |
|||||||
|
Accounts payable |
$ |
5,255 |
$ |
7,812 |
|||
|
Accrued liabilities |
27,801 |
26,563 |
|||||
|
Operating lease obligations |
5,102 |
— |
|||||
|
Finance lease obligations |
1,934 |
1,937 |
|||||
|
Total current liabilities |
40,092 |
36,312 |
|||||
|
Operating lease obligations, net of current portion |
45,694 |
— |
|||||
|
Finance lease obligations, net of current portion |
429 |
1,375 |
|||||
|
Debt |
75,184 |
74,477 |
|||||
|
Other long-term liabilities |
— |
8,956 |
|||||
|
Total liabilities |
161,399 |
121,120 |
|||||
|
Stockholders' equity: |
|||||||
|
Common stock |
9 |
8 |
|||||
|
Accumulated other comprehensive income (loss) |
— |
(5) |
|||||
|
Additional paid-in capital |
944,559 |
678,548 |
|||||
|
Accumulated deficit |
(603,065) |
(516,712) |
|||||
|
Total stockholders' equity |
341,503 |
161,839 |
|||||
|
Total liabilities and stockholders' equity |
$ |
502,902 |
$ |
282,959 |
|||
|
|
||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
2019 |
2018 |
2019 |
2018 |
|||||||||||||
|
Revenue: |
||||||||||||||||
|
Test revenue |
$ |
52,302 |
$ |
36,350 |
$ |
91,921 |
$ |
63,403 |
||||||||
|
Other revenue |
1,173 |
956 |
2,107 |
1,574 |
||||||||||||
|
Total revenue |
53,475 |
37,306 |
94,028 |
64,977 |
||||||||||||
|
Cost of revenue |
28,006 |
20,447 |
49,260 |
38,523 |
||||||||||||
|
Research and development |
25,302 |
15,784 |
43,296 |
31,150 |
||||||||||||
|
Selling and marketing |
30,779 |
18,707 |
54,972 |
37,631 |
||||||||||||
|
General and administrative |
21,274 |
12,436 |
34,593 |
24,216 |
||||||||||||
|
Loss from operations |
(51,886) |
(30,068) |
(88,093) |
(66,543) |
||||||||||||
|
Other income, net |
1,381 |
188 |
2,019 |
1,835 |
||||||||||||
|
Interest expense |
(2,121) |
(1,791) |
(4,229) |
(3,083) |
||||||||||||
|
Net loss before taxes |
(52,626) |
(31,671) |
(90,303) |
(67,791) |
||||||||||||
|
Income tax benefit |
(3,950) |
— |
(3,950) |
— |
||||||||||||
|
Net loss |
$ |
(48,676) |
$ |
(31,671) |
$ |
(86,353) |
$ |
(67,791) |
||||||||
|
Net loss per share, basic and diluted |
$ |
(0.54) |
$ |
(0.47) |
$ |
(1.01) |
$ |
(1.12) |
||||||||
|
Shares used in computing net loss per share, basic and diluted |
90,863 |
67,807 |
85,148 |
60,775 |
||||||||||||
|
|
|||||||
|
Consolidated Statements of Cash Flows |
|||||||
|
Six Months Ended |
|||||||
|
2019 |
2018 |
||||||
|
Cash flows from operating activities: |
|||||||
|
Net loss |
$ |
(86,353) |
$ |
(67,791) |
|||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|||||||
|
Depreciation and amortization |
6,725 |
6,927 |
|||||
|
Stock-based compensation |
19,540 |
10,505 |
|||||
|
Remeasurements of liabilities associated with business combinations |
(286) |
709 |
|||||
|
Benefit from income taxes |
(3,950) |
— |
|||||
|
Other |
1,182 |
462 |
|||||
|
Changes in operating assets and liabilities, net of business acquired: |
|||||||
|
Accounts receivable |
3,153 |
(4,037) |
|||||
|
Prepaid expenses and other current assets |
(3,825) |
(512) |
|||||
|
Other assets |
2,410 |
(1,428) |
|||||
|
Accounts payable |
(3,954) |
(3,106) |
|||||
|
Accrued expenses and other liabilities |
4,267 |
(396) |
|||||
|
Net cash used in operating activities |
(61,091) |
(58,667) |
|||||
|
Cash flows from investing activities: |
|||||||
|
Purchases of marketable securities |
(20,781) |
(900) |
|||||
|
Proceeds from sales of marketable securities |
— |
19,965 |
|||||
|
Proceeds from maturities of marketable securities |
34,000 |
2,078 |
|||||
|
Acquisition of business, net of cash acquired |
3,193 |
— |
|||||
|
Purchases of property and equipment |
(8,824) |
(3,084) |
|||||
|
Net cash provided by investing activities |
7,588 |
18,059 |
|||||
|
Cash flows from financing activities: |
|||||||
|
Proceeds from public offerings of common stock, net of issuance costs |
184,490 |
53,480 |
|||||
|
Proceeds from issuance of common stock |
5,123 |
4,933 |
|||||
|
Proceeds from debt financing |
— |
19,781 |
|||||
|
Finance lease principal payments |
(1,031) |
(1,170) |
|||||
|
Net cash provided by financing activities |
188,582 |
77,024 |
|||||
|
Net increase in cash, cash equivalents and restricted cash |
135,079 |
36,416 |
|||||
|
Cash, cash equivalents and restricted cash at beginning of period |
118,164 |
17,459 |
|||||
|
Cash, cash equivalents and restricted cash at end of period |
$ |
253,243 |
$ |
53,875 |
|||
|
|
||||||||||||||||
|
Reconciliation of GAAP to |
||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
2019 |
2018 |
2019 |
2018 |
|||||||||||||
|
Research and development |
$ |
25,302 |
$ |
15,784 |
$ |
43,296 |
$ |
31,150 |
||||||||
|
Acquisition-related stock-based compensation |
(2,586) |
— |
(2,586) |
— |
||||||||||||
|
Non-GAAP research and development |
$ |
22,716 |
$ |
15,784 |
$ |
40,710 |
$ |
31,150 |
||||||||
|
Reconciliation of GAAP to Non-GAAP General and Administrative Expense |
||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
2019 |
2018 |
2019 |
2018 |
|||||||||||||
|
General and administrative |
$ |
21,274 |
$ |
12,436 |
$ |
34,593 |
$ |
24,216 |
||||||||
|
Acquisition-related post-combination expense |
(3,212) |
— |
(3,212) |
— |
||||||||||||
|
Non-GAAP general and administrative |
$ |
18,062 |
$ |
12,436 |
$ |
31,381 |
$ |
24,216 |
||||||||
|
Reconciliation of Net Loss to Non-GAAP Net Loss Per Share |
||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
2019 |
2018 |
2019 |
2018 |
|||||||||||||
|
Net loss |
$ |
(48,676) |
$ |
(31,671) |
$ |
(86,353) |
$ |
(67,791) |
||||||||
|
Acquisition-related stock-based compensation |
2,586 |
— |
2,586 |
— |
||||||||||||
|
Acquisition-related post-combination expense |
3,212 |
— |
3,212 |
— |
||||||||||||
|
Acquisition-related income tax benefit |
(3,950) |
— |
(3,950) |
— |
||||||||||||
|
Non-GAAP net loss |
$ |
(46,828) |
$ |
(31,671) |
$ |
(84,505) |
$ |
(67,791) |
||||||||
|
Non-GAAP net loss per share, basic and diluted |
$ |
(0.52) |
$ |
(0.47) |
$ |
(0.99) |
$ |
(1.12) |
||||||||
|
Shares used in computing net loss per share, basic and diluted |
90,863 |
67,807 |
85,148 |
60,775 |
||||||||||||
|
|
||||||||
|
Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn |
||||||||
|
Three Months |
Three Months |
Six Months |
||||||
|
Net cash used in operating activities |
(28,366) |
(32,725) |
(61,091) |
|||||
|
Net cash provided by (used in) investing activities |
(17,545) |
25,133 |
7,588 |
|||||
|
Net cash provided by (used in) financing activities |
186,120 |
2,462 |
188,582 |
|||||
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
140,209 |
(5,130) |
135,079 |
|||||
|
Adjustments: |
||||||||
|
Purchases of investments |
20,781 |
— |
20,781 |
|||||
|
Maturities of investments |
(6,000) |
(28,000) |
(34,000) |
|||||
|
Proceeds from public offering of common stock, net of issuance costs |
(184,490) |
— |
(184,490) |
|||||
|
Proceeds from exercises of warrants |
(88) |
(25) |
(113) |
|||||
|
Cash burn |
(29,588) |
(33,155) |
(62,743) |
|||||
Contact:
(628) 213-3369
View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-reports-53-5-million-in-quarterly-revenue-driven-by-more-than-111-000-samples-in-quarterly-volume-300897506.html
SOURCE


Five Star Senior Living Inc. Announces Appointment of Margaret Wigglesworth as Senior Vice President and Chief Operating Officer
Majesco To Present At SVIA’s Digital Insurance Leadership Series: On Demand Insurance Workshop
Advisor News
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
More Advisor NewsAnnuity News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity NewsHealth/Employee Benefits News
- GOVERNOR HOCHUL TAKES ACTIONS TO PROTECT MEDICAID COVERAGE FOR NEARLY 2 MILLION NEW YORKERS
- Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
- Hooksett, Auburn, Candia, Londonderry schools face steep SchoolCare health insurance hikes
- 'Everybody missed this': Nevada's state worker insurance mismanaged for years, officials say
- Picking Medicare insurance plan is daunting task – Healthful Hints
More Health/Employee Benefits NewsLife Insurance News
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- Nebraska widow’s big win against life insurer in legal limbo
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
More Life Insurance News